CollPlant And Stratasys Begin Pre-Clinical Study Of 3D-Printed 200cc Regenerative Breast Implants Using CollPlant's rhCollagen-Based Bioinks On Stratasys' Origin Printer

Author: Benzinga Newsdesk | August 19, 2024 08:32am
3D Printed Breast implants consisting of 200cc in volume of CollPlant's rhCollagen-based bioinks produced on a Stratasys' Origin® printer to be tested Technology innovation addresses a $3.0 billion market opportunity Study to focus on ability of implants to grow natural breast tissue and completely degrade over time In a significant step in the advancement of regenerative medicine, CollPlant Biotechnologies (NASDAQ:CLGN) and Stratasys Ltd. (NASDAQ:SSYS) today announced the initiation of a pre-clinical study with 200cc commercial-sized regenerative implants printed on a Stratasys Origin® 3D printer. The collaboration between CollPlant and Stratasys is currently focused on the development of a bioprinting solution for CollPlant's breast implants, in addition to finding solutions to scale-up the implant's fabrication process. The study is intended to test the ability of the implants to promote the growth of natural breast tissue and completely degrade over time. CollPlant's novel breast implants have been designed to regenerate an individual's natural breast tissue without eliciting an immune response, and could provide a revolutionary alternative for both reconstructive and aesthetic procedures, which represents a significant portion of the overall $3 billion addressable breast implant market.

Posted In: CLGN SSYS